SOLID FORMS OF {5-CYCLOPROPYL-2-[2-(3,6-DIFLUORO¬PYRIDIN-2-YLAMINO)-PYRIDIN-4-YL]-PYRIDO[3,4-D]PYRIMIDIN-4-YL }-( (S)-3,3-DIMETHYL-PIPERIDIN-4-YL)-AMINE

1 . A crystalline Form II of Compound 1:

2 . The crystalline Form II of Compound 1 of claim 1 , wherein the crystalline Form II of Compound 1 is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that depicted in FIG. 1 when measured using CuK α radiation.

3 . The crystalline Form II of Compound 1 of claim 1 or 2 , wherein the crystalline Form II of Compound 1 is characterized by an XRPD pattern when measured using CuK α radiation comprising characteristic peaks, expressed in degrees 2-theta (±0.2), at 8.1, 9.6, and 10.9.

4 . The crystalline Form II of Compound 1 of claim 3 , wherein the crystalline Form II of Compound 1 is further characterized by an XRPD pattern when measured using CuK α radiation comprising one or more additional characteristic peaks, expressed in degrees 2-theta (±0.2), selected from 10.2 and 13.2.

5 . The crystalline Form II of Compound 1 of any one of claims 1-4 , wherein the crystalline Form II of Compound 1 is characterized by an XRPD pattern when measured using CuK α radiation that does not exhibit a peak at 4.3 degrees 2-theta (±0.2).

6 . The crystalline Form II of Compound 1 of any one of claims 1-5 , wherein the crystalline Form II of Compound 1 is characterized by an XRPD pattern when measured using CuK α radiation that does not exhibit a peak at 5.6 degrees 2-theta (±0.2).

7 . The crystalline Form II of Compound 1 of any one of claims 1-6 , wherein the crystalline Form II of Compound 1 is characterized by an XRPD pattern when measured using CuK α radiation comprising an absence of peaks, expressed in degrees 2-theta, from about 3 to about 4.8.

8 . The crystalline Form II of Compound 1 of any one of claims 1-7 , wherein the crystalline Form II of Compound 1 is characterized by an XRPD pattern when measured using CuK α radiation comprising an absence of peaks, expressed in degrees 2-theta, from about 4.8 to about 6.

9 . The crystalline Form II of Compound 1 of any one of claims 1-8 , wherein the crystalline Form II of Compound 1 is characterized by an XRPD pattern when measured using CuK α radiation comprising an absence of peaks, expressed in degrees 2-theta, from about 3 to about 7.

10 . The crystalline Form II of Compound 1 of any one of claims 1-9 , wherein the crystalline Form II of Compound 1 is characterized by an XRPD pattern when measured using CuK α radiation comprising an absence of peaks, expressed in degrees 2-theta, from about 3 to about 7.5.

11 . The crystalline Form II of Compound 1 of any one of claims 1-10 , wherein the crystalline Form II of Compound 1 is characterized by an XRPD pattern when measured using CuK α radiation comprising an absence of peaks, expressed in degrees 2-theta, from about 11.2 to about 12.5.

12 . The crystalline Form II of Compound 1 of any one of claims 1-11 , wherein the crystalline Form II of Compound 1 is characterized by an XRPD pattern when measured using CuK α radiation comprising only four peaks, expressed in degrees 2-theta, from about 7 to about 12.

13 . The crystalline Form II of Compound 1 of any one of claims 1-12 , wherein the crystalline Form II of Compound 1 is characterized by a differential scanning calorimetry (DSC) thermogram substantially similar to that depicted in FIG. 2 .

14 . The crystalline Form II of Compound 1 of any one of claims 1-13 , wherein the crystalline Form II of Compound 1 is characterized by a DSC thermogram comprising an endotherm comprising an onset temperature (T m ) of about 120.1±2.0° C.

15 . The crystalline Form II of Compound 1 of any one of claims 1-14 , wherein the crystalline Form II of Compound 1 is characterized by a DSC thermogram comprising a peak temperature (T max ) of about 120.41° C.

16 . The crystalline Form II of Compound 1 of any one of claims 1-15 , wherein the crystalline Form II of Compound 1 is characterized by a DSC thermogram comprising an enthalpy of the endothermic transition (AH) of about 0.584±0.03 J/g.

17 . The crystalline Form II of Compound 1 of any one of claims 1-16 , wherein the crystalline Form II of Compound 1 is characterized by a thermogravimetric analysis (TGA) thermogram substantially similar to that depicted in FIG. 3 .

18 . The crystalline Form II of Compound 1 of any one of claims 1-17 , wherein the crystalline Form II of Compound 1 is characterized by a TGA thermogram comprising a weight loss of about (0.262±0.013)% up to 120° C.

19 . The crystalline Form II of Compound 1 of any one of claims 1-18 , wherein the crystalline Form II of Compound 1 is characterized by a TGA thermogram comprising a weight loss of about (0.360±0.018)% up to 220° C.

20 . The crystalline Form II of Compound 1 of any one of claims 1-19 , wherein the crystalline Form II of Compound 1 is obtained by phase equilibration in methyl iso-butyl acetone, n-butyl alcohol, methyl tert-butyl ether, ethyl acetate, iso-butyl acetate, iso-propyl acetate, or THF at about 25±5° C. or about 50±5° C.

21 . The crystalline Form II of Compound 1 of any one of claims 1-20 , wherein the crystalline Form II of Compound 1 is obtained by phase equilibration in dichloromethane and methyl ethyl ketone at about 50° C.

22 . The crystalline Form II of Compound 1 of any one of claims 1-21 , wherein the crystalline Form II of Compound 1 is substantially free of impurities.

23 . The crystalline Form II of Compound 1 of any one of claims 1-22 , wherein the crystalline Form II of Compound 1 is substantially free of amorphous forms of Compound 1.

24 . A composition comprising the crystalline Form II of Compound 1 of claim 22 or 23 , wherein the composition comprises greater than or equal to 90% by weight of the crystalline Form II of Compound 1.

25 . The composition of claim 24 , wherein the composition comprises greater than or equal to 95% by weight of the crystalline Form II of Compound 1.

26 . The composition of claim 24 or 25 , wherein the composition comprises greater than or equal to 99% by weight of the crystalline Form II of Compound 1.

27 . A composition comprising the crystalline Form II of Compound 1 of claim 22 or 23 , wherein the molar ratio of the amount of Form II of Compound 1 to the sum of amounts of other forms in the composition is equal to or greater than 90:10.

28 . The composition of claim 27 , wherein the molar ratio of the amount of Form II of Compound 1 to the sum of amounts of the other forms in the composition is equal to or greater than 95:5.

29 . The composition of claim 27 or 28 , wherein the molar ratio of the amount of Form II of Compound 1 to the sum of amounts of the other forms in the composition is equal to or greater than 99:1.

30 . A crystalline Form III of Compound 1:

31 . The crystalline Form III of Compound 1 of claim 30 , wherein the crystalline Form III of Compound 1 is characterized by an X-ray powder diffraction (XRPD) pattern substantially similar to that depicted in FIG. 4 when measured using CuK α radiation.

32 . The crystalline Form III of Compound 1 of claim 30 or 31 , wherein the crystalline Form III of Compound 1 is characterized by an XRPD pattern comprising three or more characteristic peaks, expressed in degrees 2-theta (±0.2), of 4.3, 5.6, and 11.8 when measured using CuK α radiation.

33 . The crystalline Form III of Compound 1 of any one of claims 30-32 , wherein the crystalline Form III of Compound 1 is characterized by an XRPD pattern comprising an additional characteristic peak, expressed in degrees 2-theta (±0.2), of 6.7 when measured using CuK α radiation.

34 . The crystalline Form III of Compound 1 of any one of claims 30-33 , wherein the crystalline Form III of Compound 1 is characterized by a differential scanning calorimetry (DSC) thermogram substantially similar to that depicted in FIG. 5 .

35 . The crystalline Form III of Compound 1 of any one of claims 30-34 , wherein the crystalline Form III of Compound 1 is characterized by a DSC thermogram comprising an endotherm comprising an onset temperature (T m ) of about 62.93±2.0° C.

36 . The crystalline Form III of Compound 1 of any one of claims 30-35 , wherein the crystalline Form III of Compound 1 is characterized by a DSC thermogram comprising a peak temperature (T max ) of about 93.28±2.0° C.

37 . The crystalline Form III of Compound 1 of any one of claims 30-36 , wherein the crystalline Form III of Compound 1 is characterized by a DSC thermogram comprising an enthalpy of the endothermic transition (AH) of about 80.80±4.0 J/g.

38 . The crystalline Form III of Compound 1 of any one of claims 30-37 , wherein the crystalline Form III of Compound 1 is characterized by a thermogravimetric analysis (TGA) thermogram substantially similar to that depicted in FIG. 6 .

39 . The crystalline Form III of Compound 1 of any one of claims 30-38 , wherein the crystalline Form III of Compound 1 is characterized by a TGA thermogram comprising a weight loss of about (4.255±0.2)% up to 75° C.

40 . The crystalline Form III of Compound 1 of any one of claims 30-39 , wherein the crystalline Form III of Compound 1 is characterized by a TGA thermogram comprising a weight loss of about (1.240±0.060)% from 75° C. up to 175° C.

41 . The crystalline Form III of Compound 1 of any one of claims 30-40 , wherein the crystalline Form III of Compound 1 is obtained by phase equilibration in 1,4-dioxane at about 50±5° C.

42 . The crystalline Form III of Compound 1 of any one of claims 30-41 , wherein the crystalline Form III of Compound 1 is substantially free of impurities.

43 . The crystalline Form III of Compound 1 of any one of claims 30-42 , wherein the crystalline Form III of Compound 1 is substantially free of amorphous forms of Compound 1.

44 . A composition comprising the crystalline Form III of Compound 1 of claim 42 or 43 , wherein the composition comprises greater than or equal to 90% by weight of the crystalline Form III of Compound 1.

45 . The composition of claim 44 , wherein the composition comprises greater than or equal to 95% by weight of the crystalline Form III of Compound 1.

46 . The composition of claim 44 or 45 , wherein the composition comprises greater than or equal to 99% by weight of the crystalline Form III of Compound 1.

47 . A composition comprising the crystalline Form III of Compound 1 of claim 42 or 43 , wherein the molar ratio of the amount of Form III of Compound 1 to the sum of amounts of other forms in the composition is equal to or greater than 90:10.

48 . The composition of claim 47 , wherein the molar ratio of the amount of Form III of Compound 1 to the sum of amounts of the other forms in the composition is equal to or greater than 95:5.

49 . The composition of claim 47 or 48 , wherein the molar ratio of the amount of Form III of Compound 1 to the sum of amounts of the other forms in the composition is equal to or greater than 99:1.

50 . A pharmaceutical composition comprising a crystalline form of any one of claims 1-23 or 30-43 , or a composition of any one of claims 24-29 or 44-49 , and a pharmaceutically acceptable excipient.

51 . The pharmaceutical composition of claim 50 , wherein the pharmaceutical composition is in the form of a topical formulation.

52 . A method of preparing a crystalline Form II of Compound 1 of any one of claims 1-23 , or a composition of any one of claims 24-29 , the method comprising the steps of:

(1) providing a solution of Compound 1 in one or more solvents;

(2) precipitating the crystalline Form II of Compound 1 from the solution of Compound 1; and

(3) isolating the crystalline Form II of Compound 1.

53 . The method of claim 52 , wherein the solution of Compound 1 is provided by heating a mixture of solid Compound 1 and one or more solvents.

54 . The method of claim 52 or 53 , wherein at least one of the one or more solvents is a non-polar solvent.

55 . The method of claim 52 or 53 , wherein at least one of the one or more solvents is a polar solvent.

56 . The method of any one of claims 52-55 , wherein at least one of the one or more solvents is an aprotic solvent.

57 . The method of any one of claims 52-55 , wherein at least one of the one or more solvents is a protic solvent.

58 . The method of claim 52 or 53 , wherein at least one of the one or more solvents is acetonitrile, dichloromethane, dimethylformamide, 2-methoxy-ethanol, methyl iso-butyl ketone, acetone, n-butyl alcohol, methyl tert-butyl ether, ethyl acetate, heptane, isobutyl acetate, isopropyl acetate, methyl ethyl ketone, tetrahydrofuran, or dimethyl sulfoxide.

59 . The method of any one of claims 52-58 , wherein the solution of Compound 1 is saturated or supersaturated.

60 . The method of any one of claims 52-59 , wherein the precipitating step comprises one or more of phase equilibration, evaporation, anti-solvent addition, reverse addition, and cooling of a saturated solution.

61 . The method of any one of claims 52-60 , wherein the precipitating step comprises addition of one or more seed crystals of crystalline Form II of Compound 1.

62 . The method of claim 60 , wherein the precipitating step comprises phase equilibration in methyl iso-butyl acetone, n-butyl alcohol, methyl tert-butyl ether, ethyl acetate, iso-butyl acetate, iso-propyl acetate, or THF.

63 . The method of claim 62 , wherein the phase equilibration is performed between about 25±5° C. and about 50±5° C.

64 . The method of claim 60 , wherein the precipitating step comprises phase equilibration in dichloromethane or methyl ethyl ketone.

65 . The method of claim 64 , wherein the phase equilibration is performed at about 50±5° C.

66 . The method of claim 60 , wherein the precipitating step comprises anti-solvent addition to a solution of Compound 1 in dimethylformamide, 2-methoxy-ethanol, or dimethyl sulfoxide.

67 . The method of claim 66 , wherein the anti-solvent is methyl tert-butyl ether or acetonitrile.

68 . The method of claim 60 , wherein the precipitating step comprises reverse addition of an anti-solvent to a solution of Compound 1 in dimethylformamide, 2-methoxy-ethanol, or dimethyl sulfoxide.

69 . The method of claim 68 , wherein the anti-solvent is methyl tert-butyl ether or acetonitrile.

70 . A method of preparing a crystalline Form III of Compound 1 of any one of claims 30-43 , or a composition of any one of claims 44-49 , the method comprising the steps of:

(1) providing a solution of Compound 1 in one or more solvents;

(2) precipitating the crystalline Form III of Compound 1 from the solution of Compound 1; and

(3) isolating the crystalline Form III of Compound 1.

71 . The method of claim 70 , wherein the solution of Compound 1 is provided by heating a mixture of solid Compound 1 and one or more solvents.

72 . The method of claim 70 or 71 , wherein at least one of the one or more solvents is a non-polar solvent.

73 . The method of claim 70 or 71 , wherein at least one of the one or more solvents is a polar solvent.

74 . The method of any one of claims 70-73 , wherein at least one of the one or more solvents is an aprotic solvent.

75 . The method of any one of claims 70-73 , wherein at least one of the one or more solvents is a protic solvent.

76 . The method of claim 70 or 71 , wherein at least one of the one or more solvents is 1,4-dioxane or n-propanol.

77 . The method of any one of claims 70-76 , wherein the solution of Compound 1 is saturated or supersaturated.

78 . The method of claim 70 , wherein the precipitating step comprises one or more of phase equilibration, evaporation, anti-solvent addition, reverse addition, and cooling of a saturated solution.

79 . The method of any one of claims 70-78 , wherein the precipitating step comprises addition of one or more seed crystals of crystalline Form III of Compound 1.

80 . The method of claim 78 , wherein the precipitating step comprises phase equilibration in 1,4-dioxane.

81 . The method of claim 80 , wherein the phase equilibration is performed at about 50±5° C.

82 . A method for treating cancer in a subject in need thereof, comprising administering to the subject a crystalline form of any one of claims 1-23 or 30-43 , a composition of any one of claims 24-29 or 44-49 , or a pharmaceutical composition of claim 50 or 51 .

83 . The method of claim 82 , wherein the cancer is basal cell carcinoma, a solid tumor, or acute myeloid leukemia.

84 . A crystalline form of any one of claims 1-23 or 30-43 , a composition of any one of claims 24-29 or 44-49 , or a pharmaceutical composition of claim 50 or 51 for use in treating cancer in a subject in need thereof.

85 . The crystalline form of claim 84 , wherein the cancer is basal cell carcinoma, a solid tumor, or acute myeloid leukemia.

86 . A use of a crystalline form of any one of claims 1-23 or 30-43 , a composition of any one of claims 24-29 or 44-49 , or a pharmaceutical composition of claim 50 or 51 for the treatment of cancer in a subject in need thereof.

87 . Use of a crystalline form of any one of claims 1-23 or 30-43 , a composition of any one of claims 24-29 or 44-49 , or a pharmaceutical composition of claim 50 or 51 in the manufacture of a medicament for the treatment of basal cell carcinoma, solid tumors, or acute myeloid leukemia in a subject in need thereof.

88 . The use of claim 86 or 87 , wherein the cancer is basal cell carcinoma, a solid tumor, or acute myeloid leukemia.

89 . A kit comprising a crystalline form of any one of claims 1-23 or 30-43 , a composition of any one of claims 24-29 or 44-49 , or a pharmaceutical composition of claim 50 or 51 , and instructions for using the crystalline form, composition, or pharmaceutical composition.